טוען...
Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
BACKGROUND: p-Boronophenylalanine ((10)BPA) is a powerful (10)B drug used in current clinical trials of BNCT. For BNCT to be successful, a high (500 mg/kg) dose of (10)BPA must be administered over a few hours. Here, we report BNCT efficacy after rapid, ultralow-dose administration of either tumor v...
שמור ב:
| הוצא לאור ב: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7809749/ https://ncbi.nlm.nih.gov/pubmed/33446132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07760-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|